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Abstract
Fertility is important to women and men with cancer. While options for fertility preservation
(FP) are available, knowledge regarding the medical application of FP is lacking. Therefore
we examined FP practices for cancer patients among reproductive endocrinologists (REs). A
36 item survey was sent to board-certified REs. 98% of respondents reported counseling
women with cancer about FP options. Oocyte and embryo cryopreservation were universally
offered by these providers, but variability was noted in reported management of these cases
—particularly for women with breast cancer. 86% of the respondents reported using letrozole
during controlled ovarian stimulation (COS) in patients with estrogen receptor positive (ER+)
breast cancer to minimize patient exposure to estrogen. 49% of respondents who reported
using letrozole in COS for patients with ER+ breast cancer reported that they would also use
letrozole in COS for women with ER negative breast cancer. Variability was also noted in the
management of FP for men with cancer. 83% of participants reported counseling men about
sperm banking with 22% recommending against banking for men previously exposed to che-
motherapy. Overall, 79% of respondents reported knowledge of American Society for Clinical
Oncology FP guidelines—knowledge that was associated with providers offering gonadal tis-
sue cryopreservation (RR 1.82, 95%CI 1.14–2.90). These findings demonstrate that RE
management of FP in cancer patients varies. Although some variability may be dictated by
local resources, standardization of FP practices and communication with treating oncologists
may help ensure consistent recommendations and outcomes for patients seeking FP.
Introduction
Future fertility is important to young women and men diagnosed with cancer [1–3]. Awareness
of fertility preservation (FP) options has improved over recent years, and more patients are
being referred by their oncologists to discuss FP options with reproductive specialists [4–7].
Most FP options require the application of Artificial Reproductive Technologies (ARTs)—
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established technologies most commonly used to treat infertility patients [8]. ARTs include oo-
cyte and embryo cryopreservation for women, and intracytoplasmic sperm injection of oocytes
using cryopreserved spermatozoa for men (Table 1). Experimental FP options requiring testic-
ular or ovarian tissue cryopreservation are available for prepubertal patients and for women
who lack the time required for established FP methods [1,9,10].
Both experimental and established FP services are provided by Reproductive Endocrinolo-
gists—physicians trained in both Obstetrics and Gynecology and in Reproductive Endocrinol-
ogy, and collaborating urologists. RE experience in providing FP services to patients with
cancer is growing, but as recently pointed out in the 2013 update to the ASCO guidelines for
fertility preservation for patients with cancer, there is a paucity of well-designed studies and
outcome data focused on the application, success, and effects of FP on patients with cancer [1].
Given the lack of data available for FP outcomes in patients with cancer, concerns have been
raised over the application of conventional ART practices in cancer patients [3,11]. Many of
these concerns focus on the gonadotropin stimulation regimens used to prepare the ovaries for
oocyte harvest—a treatment commonly referred to as controlled ovarian stimulation (COS).
Traditional COS regimens have centered around normal physiologic events of the menstrual
cycle to stimulate recruitment of multiple oocyte-containing, ovarian follicles. This process re-
quires appropriate timing with the menstrual cycle and it associated elevations in serum estra-
diol levels (Fig 1) [8]. COS is generally well tolerated, but there are associated risks that may be
particularly undesirable for women with cancer [3]. For instance, there is a theoretical risk that
the supraphysiologic estrogen levels resulting from COS could stimulate the growth of estro-
gen-sensitive tumors or increase the risk of cancer recurrence [3]. Women undergoing COS
are also at risk for ovarian hyperstimulation syndrome (OHSS) and thromboembolic events
which could delay or complicate planned cancer treatments [11]. Furthermore, for women
who need to initiate cancer treatment quickly the time required for traditional COS regimens
can be prohibitive. Concerns over such risks have led physician-scientists to propose modifica-
tions in traditional COS protocols including the incorporation of letrozole into COS for
women with breast cancer to curb rising estradiol levels, and initiating COS randomly in the
menstrual cycle to speed up the time to oocyte harvest for women with little time available to
delay cancer treatment (Fig 1) [1,12–15].
Whether or not modifications for cancer patients undergoing FP procedures have been as-
similated into FP practice is unknown. We conducted a national survey of REs to clarify defi-
ciencies and knowledge gaps in current FP practice for patients with cancer and inform
improvements in future practice.
Materials and Methods
Survey Development and Content
We developed a questionnaire that was piloted among RE’s at the Midwest Reproductive Sym-
posium meeting held in Chicago, Illinois, in May 2012. The survey focused on three areas: 1)
Table 1. Standard and experimental options utilizing ART for FP in cancer patients [1,9,10].
ART FP options for women
Oocyte banking Established
Embryo banking Established
Ovarian tissue cryopreservation Experimental
ART FP options for men
Sperm banking with in vitro fertilization and intracytoplasmic sperm injection Established
Testicular tissue cryopreservation Experimental
doi:10.1371/journal.pone.0127335.t001
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Provider demographics; 2) Fertility preservation for women with cancer; and 3) Fertility pres-
ervation for men with cancer. Several questions regarding contraceptive counseling were also
asked. The final survey consisted of 36 questions (S1 Appendix).
Survey Distribution
This cross-sectional survey was approved by the Human Research Protection Office, the insti-
tutional review board (IRB) at Washington University. Per our IRB, respondents provided im-
plied consent by responding to the survey. We used the Society for Reproductive
Endocrinology and Infertility (SREI) membership directory (www.socrei.org) to identify par-
ticipants. SREI represents fellowship-trained Reproductive Endocrinologists who are board-
certified in both Obstetrics and Gynecology and the subspecialty of Reproductive Endocrinolo-
gy by the American Board of Obstetrics and Gynecology. 791 members were identified. We ex-
cluded members without email addresses (n = 5), members practicing outside the United
States (n = 20), and members from our own practice (n = 7). 759 e-mail invitations containing
a link to the anonymous web-based survey were sent on August 3, 2012. Three reminders were
sent between August and October, 2012. Participants had 8 weeks to complete the survey.
Data Analysis
The survey was implemented using SurveyMonkey (Portland, OR). Results were transferred to
SPSS version 20 (Armonk, NY) for analysis. Frequencies and proportions were summarized
Fig 1. Standard COS protocols and timing in menstrual cycle. Events depicted above the grid occur in natural menstrual cycles whereas events depicted
below the grid depict timing of administration of medications for COS protocols. Color in the grid is representative of rising estradiol levels during the
menstrual cycle and COS protocols.
doi:10.1371/journal.pone.0127335.g001
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for physician demographics and practices. Relative risks (RR) with 95% confidence intervals
were estimated to compare knowledge of ASCO guidelines and practices.
Results
The response rate was 13% (88/684). 51 e-mail addresses were undeliverable, and auto-re-
sponses indicated 24 addressees were unavailable. 596 invitations were unanswered.
Provider Demographics
Table 2 summarizes respondent demographics. 51% were male, and 49% were female. The av-
erage age of survey participants was 46 years, and participants represented both academic
(61%) and private (39%) practices. Overall, 98% of respondents reported offering FP services
for patients with cancer. Of these, 78% reported an affiliation with a cancer center and 71% re-
ported familiarity with ASCO guidelines for fertility preservation in patients with cancer. Re-
spondents came from 28 different states.
Fertility Preservation for Women with Cancer: Controlled Ovarian
Stimulation
Physicians’ responses varied regarding COS preference for FP cases in women with cancer. Re-
garding how to dose gonadotropins for COS, most physicians would either use a standard
amount of gonadotropin (45%) or higher doses (45%), with only 10% stating that they would
use a gentler stimulation protocol with lower doses of gonadotropins for FP patients with can-
cer. Survey respondents also differed in their preferred COS protocol for FP. Most (80%) pre-
ferred a GnRH agonist-based stimulation protocol (a protocol associated with a longer
stimulation time than other options [11]), while others preferred a GnRH antagonist-based
protocol (8%). The remainder did not have a preference, stating they tailored the protocol to
the patient (12%).
Regarding preferred agent for inducing oocyte maturation in COS, 80% of respondents pre-
ferred a standard hCG trigger, and 20% preferred GnRH agonist trigger (a modification to tra-
ditional protocols that has been proposed to reduce the risk of ovarian hyperstimulation
syndrome in women with cancer undergoing COS for FP [11,16,17]). This finding was in line
with stimulation protocol preferences, as hCG is used concurrently with a GnRH agonist stim-
ulation regimen, and a GnRH agonist trigger can be utilized in GnRH antagonist cycles.
Another aspect of stimulation in which survey respondents disagreed was whether or not to
start COS randomly (e.g. not early in the follicular phase). Approximately half (48%) of
Table 2. Respondent demographics.
Characteristic N = 89
Gender Male 49% (44)
Female 47% (42)
Chose not to answer 3% (3)
Age (mean years ± SD) 48.8 ± 11.8
Practice Setting Private Practice 38% (34)
Academic 60% (54)
Chose not to answer 1% (1)
Associated with a cancer center (n) 78% (65)
Knowledge of ASCO FP guidelines (n) 78% (65)
doi:10.1371/journal.pone.0127335.t002
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surveyed physicians stated that they would randomly start COS for FP patients, while the re-
mainder, 52%, would not (random starts are modifications to traditional protocols to speed the
time to oocyte retrieval [11,18]).
Ultimately, 40% of physicians would cancel FP COS if the patient had poor ovarian re-
sponse to gonadotropin—commonly defined as fewer than 3 developing ovarian follicles. The
remaining 60% would proceed to retrieval regardless of the number of developing follicles.
Many respondents commented that FP patients often only have “one chance” at stimulation,
so cancellation was not an option.
Several survey questions focused on the management of COS for oocyte and embryo cryo-
preservation in patients with breast cancer—specifically on the use of letrozole to blunt estro-
gen exposure during COS. 86% of the respondents reported using letrozole during COS in
patients with estrogen receptor positive (ER+) breast cancer to minimize patient exposure to
estrogen. 20% of respondents stated they had used tamoxifen as an adjuvant to COS in ER
+ breast cancer patients as well. Comments from those reporting they used letrozole in COS
for women with ER+ breast cancer included the following: “Yes, to reduce estrogen as used in
published data,” “Based on literature and recommendation of oncologist,” “Most published ex-
perience in the literature,” “To diminish estradiol production based on Oktay protocol; reas-
sures patients and oncologists who are nervous with supraphysiologic estradiol levels.” One
respondent stated they would not offer COS at all to women with ER+ cancer. Comments from
the 14% who disagreed with using letrozole in COS for women with ER+ breast cancer includ-
ed the following: “Not much change in estradiol, estradiol levels much higher in pregnancy
anyway,” “Show me the evidence!,” “Oncologists at our center don't feel that there is any ad-
vantage for short term.”
49% of respondents who reported using letrozole in COS for patients with ER+ breast can-
cer reported that they would also use letrozole in COS for women with ER negative breast can-
cer. Comments from these respondents included the following: “Try to limit estradiol exposure
in any breast cancer,” “Estradiol has activity besides through classic receptor mechanism,”
“Oncologist still prefers that we do”, and “Due to limited safety data for process.” Some respon-
dents stated they (20%) also had used tamoxifen when stimulating ER+ breast cancer patients.
Fertility Preservation for Women with Cancer: Ovarian Tissue
Cryopreservation
20% of survey respondents reported offering ovarian tissue cryopreservation as an FP option.
Interestingly, 100% of the survey participants who offer ovarian tissue cryopreservation were
also familiar with ASCO guidelines, while none of the physicians who were unfamiliar with
ASCO guidelines offer the option of ovarian tissue cryopreservation (16/63 vs. 0/17).
Fertility Preservation for Men
83% of respondents reported offering semen cryopreservation services to male patients with
cancer. 22% of those offering sperm banking responded that they do not recommend banking
to men with cancer who have already been exposed to chemotherapy. 33% reported offering
electroejaculation services, and 84% reported offering emergent testicular sperm extraction
(TESE)—options for men who are unable to provide a semen specimen through masturbation.
A larger proportion of REs who were familiar with ASCO guidelines offered TESE (RR 1.61,
95% CI 1.04–2.50). This result combined with those offering OTC revealed that overall those
who offered gonadal cryopreservation were more likely to also be familiar with ASCO guide-
lines (1.82, 95% CI 1.14–2.90).
Approaches to Fertility Preservation for Cancer Patients Vary
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Contraceptive Counseling
83% of respondents reported advising female patients with cancer to contracept during chemo-
therapy while 59% of respondents reported counseling men to contracept during chemothera-
py. Comments associated with responses included the following: “I leave this to the med
oncologists,” “discussion usually left to others on the team,” “doesn’t come up in our consults,”
“I don’t, but I should.”
Discussion
To our knowledge this is the first survey of REs on practice patterns, protocols, and preferences
in providing FP services for people with cancer. Our results highlight a lack of consistency in
FP practice—specifically in management of COS protocols for women with cancer, recommen-
dations regarding banking of sperm after initiation of chemotherapy for men, and counseling
regarding contraception for both men and women with cancer. We believe this latter point is
particularly important in light of the fact that while we emphasize that fertility is at risk with
many cancer treatments, pregnancy is still possible. The FP consultation is an ideal time to dis-
cuss contraceptive options—especially in young breast cancer patients who often stop oral con-
traceptive pills after diagnosis. We also believe the lack of consensus in responses amongst
providers is consistent with the recent update to the ASCO guidelines for fertility preservation
in patients with cancer which states, “fertility preservation methods are still applied relatively
infrequently in patients with cancer, limiting greater knowledge about the success and effects
of different interventions” [1]. Thus improvements in provider collaboration are required to
optimize treatment outcomes and survivorship for young patients with cancer.
Our results highlight a variety of opinions and preferences among REs regarding COS in
women for oocyte and embryo cryopreservation. 90% of responding physicians reported they
would use standard (45%) or higher doses of gonadotropins for COS (45%). Previous work has
demonstrated diminished ovarian reserve in women with cancer which may require more go-
nadotropin. On the other hand there are concerns that the supraphysiologic levels of estrogen
associated with COS could result in OHSS or increase the risk for thromboembolism [1,11].
Given this risk, it is not surprising that some of the respondents stated that they would use
lower doses of gonadotropin (10%). Which approach is best is unknown.
Our results also show disagreement among REs regarding the use of letrozole or other estro-
gen-opposing agents in COS for women with breast cancer. The only safety data on COS in
women with breast cancer is from a 2008 study by Azim et al. from JCO. In this study, women
with breast cancer pursuing FP with oocyte or embryo cryopreservation were placed on a
GnRH antagonist-based COS protocol incorporating letrozole to keep circulating estradiol lev-
els low [13]. There was no difference in disease recurrence between the 79 women who under-
went COS versus the 136 women who did not with 23 months of follow up in the COS group
and 33 months in the control group. In an editorial response to the study concerns were raised
over the small study size, limited follow up, and lack of randomization. In the editorial, Dr.
Ann Partridge cautioned that, “Legitimate concern remains that the ovarian stimulation could
have a negative impact on outcome. More extended follow-up is critical, particularly for
women with hormone receptor-positive disease who have a risk of disease recurrence that ex-
tends for many years.”On the other hand, Partridge acknowledged, “decisions in the clinic
cannot always wait until more solid data are available.” Given that Dr. Azim’s data using
GnRH antagonist-based COS is the only data available regarding safety of COS in women with
cancer, it is surprising to note that only 12% of the respondents in this study reported that they
preferred GnRH antagonist-based COS for women with cancer.
Approaches to Fertility Preservation for Cancer Patients Vary
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Several groups have published reviews to help facilitate management of FP in patients with
cancer. These organizations include the International Society for Fertility Preservation[19], fer-
tiPROTEKT—a collaboration of centers in Germany, Switzerland and Austria [17], and indi-
vidual centers with an abundance of experience in providing FP for cancer patient [11,20]. All
of these documents provide guidance, but again outcome is lacking.
According to our survey, most REs are familiar with ASCO guidelines for fertility preserva-
tion in cancer patients. While these guidelines were not focused on Reproductive Endocrinolo-
gists, we believe the responses from our survey highlight the fact that the ASCO guidelines are
a source document for those providing FP services to patients with cancer. Statements regard-
ing the use of agents like letrozole as COS adjuvants for breast cancer patients and options for
contraception in cancer patients may be appropriately placed in the oncology literature
through such documents or other supplements. Our data indicate that REs who are familiar
with the ASCO guidelines are more likely to offer experimental FP options like gonadal tissue
cryopreservation. Given this, it is possible the responding providers may be more abreast of the
FP literature for cancer patients. Again we believe that the ASCO guidelines may be a forum
for REs and clinicians providing cancer care alike.
Perhaps one of the best contributions our study provides is the commentary provided by
practicing REs. Conflicting statements regarding the use of letrozole in ER+ breast cancer pa-
tients in particular draws attention to the fact that some consensus with input from oncologists
would be timely and that follow up outcome data on patients with cancer who pursue FP is
needed to ensure consistent and safe outcomes in the future[3].
There are several important limitations to our study. Our response rate was low (13%). On
the other hand, this response rate is consistent with surveys of Oncologists regarding FP
counseling and referral patterns[6,21–23]. In surveys of clinicians providing oncology care, re-
sponse rates ranged from 7% to 12.5% among physicians[21,22], and up to 22% among clinical
nurses[22]. A 32% response rate was achieved in a survey of Oncologists published in JCO in
2008 but clinicians were paid a $100 honorarium[6].
Because of our response rate, we cannot be certain our results are truly representative of RE
practice patterns. However, there was a representative sampling from both private practice and
academic centers across the country. Importantly, the physicians who responded to the survey
represent states in which the bulk of IVF takes place nationally (California, Florida, Illinois,
New Jersey, New York, and Texas)[24]. States not represented in this survey included: Arkan-
sas, Alaska, Delaware, Idaho, Iowa, Kansas, Kentucky, Maine, Minnesota, Mississippi, Ne-
braska, Nevada, New Hampshire, New Mexico, North Dakota, Oregon, South Dakota, Utah,
Vermont, West Virginia, Wisconsin, Wyoming. Of these states, there are no ART centers regis-
tered with Society for Assisted Reproductive Technologies in Alaska, Maine or Wyoming.
Among the others, in the most recent data provided by SART 12,269 cycles of ART were per-
formed of 154,412 reported nationwide—just under 8%[25]. Given this we contend that our
survey is likely representative of the majority of physicians practicing FP.
Our response rate may be secondary to repeat requests of this group to respond to surveys,
or survey fatigue [26]. We surveyed SREI members and members of the Society for Reproduc-
tive Surgeons less than one year prior to this survey achieving a 43% response rate [27]. We
cannot be certain that the people who responded to the current survey responded to the previ-
ous survey, but we doubt many people who failed to respond to our previous survey responded
to the current survey. For these reasons we estimate 25% (88/370) of eligible participants who
responded to our previous survey responded to the current survey. Also our previous survey in-
quired about a general topic in reproductive medicine. There could be less interest or decreased
level of comfort among those surveyed in the subject of FP—we suspect this is the case. Along
these same lines, it is possible that only RE specialists routinely providing FP care who are
Approaches to Fertility Preservation for Cancer Patients Vary
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abreast with the FP literature responded to our survey, thus it is possible FP practices vary
more among RE specialists who did not respond. There is also potential reporting bias in our
results as the responses are based on physician recall, rather than actual practice data.
Our data suggests that FP practice varies and it highlights important areas where attention
is needed. We believe this study is a particularly important addition to the literature as FP prac-
tice patterns amongst REs for patients with cancer have gone unreported and REs are responsi-
ble for directly applying FP options. Consistency in future practice is important as the cancer
population served by FP is young and focused on survival. Consistency in practice will ensure
their oocytes, embryos, sperm and gonadal tissue is handled appropriately for optimal fertility
treatment outcomes. Consistency will only come with collaboration and continued communi-
cation among clinicians providing FP services and Oncologists.
Supporting Information
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